You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The conditional licensure is the latest for the firm's FISH-based HPV-Associated test for cervical cancer.
The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements.
About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.
Revenue from the firm's ResponseDX test jumped 16 percent in the fourth quarter of 2014 and 22 percent for the full year.
The company's biopharma business grew 280 percent year over year, including contributions from Gentris, which Cancer Genetics bought last summer.
The company drew a first tranche of $8.5 million from the credit facility in July and has $2 million remaining on the term loan commitment.
The technical-only testing service leverages Ventana's digital pathology technology.
The decision opens up the largest market in the country to the firm's lymphoma and leukemia testing services.
The firm was not in compliance with minimum bid price and minimum stockholders' equity requirements to remain listed.
Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.
Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.
Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.
Stat News reports some health tech startups are laying off or furloughing workers.
In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.